Skip to main content

Xibrom FDA Approval History

FDA Approved: Yes (Discontinued) (First approved March 24, 2005)
Brand name: Xibrom
Generic name: bromfenac
Dosage form: Ophthalmic Solution
Company: Bausch & Lomb Inc.
Treatment for: Postoperative Ocular Inflammation

Marketing Status: Discontinued

Xibrom (bromfenac) is an ophthalmic nonsteroidal antiinflammatory drug (NSAID) for the treatment of postoperative pain and inflammation in patients who have undergone cataract extraction.

Development timeline for Xibrom

Jan 27, 2006Approval Xibrom - ISTA Pharmaceuticals, Inc. - New Indication Approved
Mar 24, 2005Approval Xibrom ISTA Pharmaceuticals, Inc. - Treatment for Ocular Inflammation Following Cataract Surgery
Jul 26, 2004FDA Accepts ISTA Pharmaceuticals' New Drug Application for Xibrom
May 25, 2004ISTA Pharmaceuticals Announces Submission of Xibrom NDA to the FDA

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.